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Ferric chloride (FeCl3) induced vascular injury is a widely used model of occlusive thrombosis that
reports platelet activation in the context of an aseptic closed vascular system. This model is based on
redox-induced endothelial cell injury, which is simple and sensitive to both anticoagulant and anti-
platelets drugs. The time required for platelet aggregation to occlude blood ﬂow gives a quantitative
measure of vascular damage that is pathologically relevant to thrombotic disease. We have reﬁned the
traditional FeCl3-induced carotid artery model making the data highly reproducible with lower
variation. This paper will describe our artiﬁces and report the role of varying the oxidative damage
by varying FeCl3 concentrations and exposure. To explore a maximum difference between experimental
groups, adjustment of the selected FeCl3 dose and exposure duration may be necessary.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. Introduction
Thrombotic cardiovascular diseases are the most common cause
of death and disability in the developed world [1–4]. The vessel
wall is a complex system that includes multiple cell types and is
inﬂuenced by multiple extrinsic factors including shear stress,
circulating blood cells, hormones and cytokines, as well as the
antioxidant status of the vessel wall [5,6]. Therefore, in vitro
experiments cannot replicate this complex environment, so
in vivo studies of animal models are critical to allow better under-
standing of mechanisms involved in thrombotic disorders [7–9].
Such studies mimic human pathology and may provide important
mechanistic information related to discovery of new pathways and
drugs, as well as important details characterizing drug effects.
Ferric chloride (FeCl3) induced vascular injury is a widely used
model of thrombosis [10,11]. This agent, applied to the outer aspect
of arteries induces oxidative damage to vascular cells [12,13], with
loss of endothelial cell protection from circulating platelets and
components of the coagulation cascade. This model is simple and
sensitive to both anticoagulant and anti-platelets drugs, and has
been performed on carotid and femoral arteries, jugular veins, and
mesenteric and cremasteric arterioles and venules in mice, rats,er B.V.
ar and Molecular Medicine,
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444 9404.
Open access under CC BY-NC-Nguinea pigs and rabbits [12–19]. In this model FeCl3 is applied to the
topical surface of an intact vessel, triggering vascular wall injury and
denudation of the endothelium via a mechanism involving the
generation of reactive oxygen species [4,14]. A recent study sug-
gested that FeCl3-induced vascular injury was erythrocyte-depen-
dent, requiring hemolysis and hemoglobin oxidation for endothelial
denudation [20,21]. One measurable parameter in this model is the
elapsed time from injury to complete vessel occlusion, measured as
blood ﬂow cessation by Doppler ﬂowmeter or under direct observa-
tion with intravital microscopy [13–15]. A range of times between 5
and 30 min has been reported in different studies in C57Bl6 mice
[12–15,22], suggesting that FeCl3 concentrations, types of anesthe-
sia, surgical techniques, mouse age and genomic background,
method of measuring blood ﬂow, and other environmental variables
have signiﬁcant effects in this model. This wide variability may be
acceptable for a single study, but it makes it very difﬁcult to
compare studies from different groups and may make detection of
subtle differences difﬁcult. In our recent serial studies of the role of
the type 2 scavenger receptor CD36 in thrombosis associated with
diet-induced atherosclerosis we have reﬁned the traditional FeCl3-
induced carotid artery model making the data highly reproducible
with lower variation [12–15,22,23]. This paper will describe and
share our skills and report different FeCl3 concentration or different
treating time induced different redox injury on thrombosis.Materials and methods
All procedures and manipulations of animals have been
approved by Institutional animal care and use committeesD license. 
W. Li et al. / Redox Biology 1 (2013) 50–55 51(IACUC) of The Cleveland Clinic in accordance with the United
States Public Health Service Policy on the Humane Care and Use of
Animals, and the NIH Guide for the Care and Use of Laboratory
Animals.
Equipment and reagents
Tools for mouse surgery are available from Fine Science Tools
(FST). Minimum necessary tools include: dissection scissor
(14502-14), forceps (11018-12) for cutting skin, scissor (14519-
14) and forceps (11050-10) for dissecting soft tissue, hemostatic
forceps (13021-12), ﬁne needle holders (12061-10), ﬁne tip
forceps [Dumont #5 (11 cm) 11254-20 and Dumont #5XL
(15 cm) 11253-10], 3/8 curve needle, 4-0 silk suture, 6-0 silk
suture, and a hook (10062-12). A black plastic coffee stir tube,
Whatman #1 ﬁlter paper cut into 12 mm pieces, 15-cm tissue
culture lids, surgical tape, a dissecting microscope (or loupes with
at least 4X magniﬁcations), heating pad with rectal temperature
monitor probe, and hair cutter were also used. For real time
observation of thrombosis we used a Leica DMLFS ﬂuorescent
microscope with an attached Gibraltar Platform (EXFO, Quebec,
Canada) and water immersion objectives at 10x, 20x and 60x
magniﬁcations. Video imaging was performed using a QImaging
Retigo Exi 12-bit mono digital camera (Surrey, Canada) and
Streampix version 3.17.2 software (Norpix, Montreal, Canada).
Ketamine (Ketaset 100 mg/ml, Fort Dodge Animal Health, IA, USA)
and xylazine (100 mg/ml, Hospira, IL, USA) were used for anesthe-
sia and rhodamine 6G (Sigma 252433-1G, 0.5 mg/ml in saline,
0.2 mm ﬁltered) was injected intravenously used to label blood
components. A stock solution of 30% FeCl3 (Anhydrous, Sigma
12321) in water was prepared and diluted prior to use at ﬁnal
concentrations of 2.5%, 5%, 7.5%, 10% and 12.5%.
Arterial injury protocol1. Eight to twelve weeks old C57Bl6 mice are anesthetized with
ketamine (100 mg/kg)/xylazine (10 mg/kg) via intraperito-
neal injection. This anesthetic method facilitates manipula-
tion of the animal during surgery and during transfer from
surgical bench to the microscope stage.2. Fur on the neck and upper chest is removed with a small
animal electric clipper. Dipilatory cream is not used.3. Mice are secured in the supine position on the lid of 15 cm
tissue culture plate using tape (about 10 cm) to secure hind
limbs and lower body, and two pieces of tape (2 cm0.5 cm)
to secure the forelegs. A 4-0 suture is wrapped around the
incisors to keep the neck straight.4. The mouse is placed with head towards the operator under a
surgical light source. A midline incision is made through the
skin from sternum to chin as shown in the line drawn in Fig. 1A.5. The structures visualized ﬁrst under the skin are the sub-
maxillary glands (Fig. 1B and D, blue arrows) which are linked
by a thin fascia (dotted line). This fascia can be dully dissected
with a hemostatic forceps exposing the manubrium (black
arrow in Fig. 1C) and the trachea (T in Fig. 1D).6. The soft tissue seen to the right of the black arrow in Fig. 1C
and the skin are held together with a forceps and a dissection
forceps is then inserted under the fascia toward the 2 o’clock
position (yellow dotted line in Fig. 1C) which is the position of
the clavicle. The fascia is then freed from the jugular vein by
opening the forceps.7. The fascia, soft tissue and skin along the yellow dotted line in
Fig. 1C are cut to expose the right jugular vein (Fig. 1D,
arrow).8. 100 ml of rhodamine 6G solution (or other drugs or ﬂuores-
cent free radical indicators) is injected into the right jugularvein to label platelets using a 1 cc syringe with a fresh 30G
needle. It is important to ﬂush the needle with the solution to
make sure that no air bubbles remain. To facilitate injection
the needle can be bent 2–3 mm from tip to a 901 angle, which
will make the tip parallel to the long axis of jugular vein
(Fig. 1D). To stabilize the syringe and keep the needle in
position the syringe is held in one hand and the needle with a
forceps in the other during the injection. After injection, the
site is held with the forceps, the vessel is clamped with a
dissection forceps, and the vein is ligated with a 6-0 suture.
It is important to perform the rhodamine injection before
exposing the left carotid artery (CA) to prevent adventitial CA
staining by the ﬂuorescent dye if leakage or bleeding occurred
during or after injection.9. The soft tissue and fascia around the left submaxillary gland
is then dully dissected and pulled toward the 7 o’clock
position (Fig. 1E) to expose the left sternocleidomastoid
muscle (blue arrow).10. The fascia (Fig. 1E, dotted line) between the left sternoclei-
domastoid muscle and the omohyoid muscle or the sterno-
hyoid muscle (Fig. 1E, green arrow) located to the left of the
trachea is then dully dissected with a hemostatic forceps.11. A needle with 6-0 silk suture (about 15 cm long) is passed
under the sternocleidomastoid muscle at the level indicated
by blue arrow in Fig. 1E and pulled laterally toward the
10 o’clock position to expose the common CA along or under the
sternohyoid muscle and/or omohyoid muscle. This procedure
must be performed with care to avoid injuring the left jugular
vein, which is located outside of the sternocleidomastoid
muscle.12. The CA is seen after pulling away the sternocleidomastoid
muscle (Fig. 1F arrow), which is accompanied by the vagus
nerve, the white structure seen in Fig. 1G (green arrow).
The very thin omohyoid muscle seen between the yellow
dotted lines in Fig. 1F is removed if it covers the CA.13. The hemostatic forceps are used to dissect the soft tissue
around the CA without touching the CA, and then ﬁne tip
forceps are used to pick up the lateral fascia around the CA
while avoiding the vagus nerve and CA. Another ﬁne tip
forcep is then used to punch a hole between the CA and vagus
nerve. A hook is passed through the hole and the CA gently
lifted so that a ﬁne tip forcep can be placed under the CA.
The hook and forceps are then in opposite directions along
the CA to strip adventitial soft tissue.14. To block background ﬂuorescence, a black plastic coffee
stirrer is cut into a 3 mm piece, pressed and cut longitudinally
to yield two pieces of ‘‘U’’ shape plastic. One piece is inserted
with forceps under the CA while gently lifting the CA with the
hook (Fig. 1H).15. To avoid drying of CA, 2–3 drops of saline are applied to the
surgical ﬁeld and the mouse and plate lid are transferred
together to the microscope stage and the 10x water lens is
placed in the appropriate position.16. Since mechanical trauma can directly injure the endothelium
and lead to thrombus formation [24] it is necessary to
observe and record vessel images to conﬁrm that no surgical
injury happens to the vessel prior to the FeCl3 injury. It is also
necessary to conﬁrm that there is no remaining tissue around
the CA, which may form a barrier and attenuate the effect of
FeCl3-induced injury.17. A paper towel is folded to make a thin and ﬁne tip and used to
carefully blot the saline around the CA (avoid touching CA) as
well as in other places in the surgical ﬁeld. This is very
important to avoid dilution of the used FeCl3 solution.18. Using a ﬁne tip forceps to pick up a piece of ﬁlter paper
(12 mm) saturated with FeCl3 solution and place directly
Fig. 1. Procedures to expose the jugular vein, injection of rhodamine 6G ﬂurescence dye into the circulation system and exposure of left carotid artery. T indicates trachea.
See text for details.
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from the CA and rinsed with saline. To aid visualization of the
blood stream the ﬁlter paper is placed toward the distal end
of the exposed CA (Fig. 1I) making sure to leave a short
segment of the proximal site (green arrow in Fig. 1I) for
observing late phase blood ﬂow.Observation of thrombi formation and the image record
Thrombus formation is identiﬁed by accumulation of the
ﬂuorescent platelets, which is observed in real-time recording
video images or under microscope. Typically, we record video for
10 s every minute for the ﬁrst 10 min and then 10 s every other
minute. Make sure to note the video frame number at each time
point for later analysis. After injury the vessel is scanned from
distal to proximal sites of the exposed segments to provide a
complete view of the initial injury, and then focus on the interest
area for further imaging. When the thrombus occupies the entiresegment it becomes difﬁcult to identify blood ﬂow in the thrombi.
To solve this issue the imaging is moved to the proximal un-
injured site (Fig. 1I, green arrow). In this site, blood ﬂow should be
still clearly identiﬁed. The end points of the experiment are: when
blood ﬂow has ceased for 430 s, or if occlusion is not seen after
30 min, the time is recorded as 30 min for statistical comparisons.Statistical analysis
One-way ANOVA (Bonferroni/Dunn) is used to determine the
differences among groups. Unpaired t test is used to determine
differences between groups. Data are represented as mean7SEM,
and Po0.05 is considered signiﬁcant.
Results and discussion
Animal models of thrombosis not only provide valuable
information about the mechanisms of thrombosis, but also are a
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Fig. 2. Effect of different concentration of FeCl3 on thrombosis. Representative video images of thrombi formation in carotid artery (CA) treated with different
concentration of FeCl3, 2.5% (A), 5% (B), 7.5% (C), and 10% (D) are shown. Blood ﬂow was from right to left. ‘‘Before’’ indicates images taken immediately prior to FeCl3
treatment. Numbers indicate time in minutes after removing the ﬁlter paper. Arrows in A indicate the tiny thrombi which were ﬁrst observed.
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be used for treatment and prevention of the atherothrombotic
diseases [10,16,21,25]. Although the FeCl3 induced vessel injury
model is a well-accepted tool for studying thrombosis, the
mechanism of FeCl3 induced vascular lesion and the determinants
initiating thrombus formation remains incompletely understood.
One established concept is that FeCl3 mediated oxidation induces
endothelial cell denudation and subsequent exposure of the
subendothelial matrix to the blood stream, thus activating the
coagulating system [4,21].
We made several reﬁnements to the FeCl3 model to enhance
its utility and reproducibility. These include: (1) exposing the CA
sufﬁciently to provide enough length (5 mm) to allow applica-
tion of the ﬁlter paper while leaving space to clearly observe
blood ﬂow by intravital microscopy; (2) stripping the adventitial
soft tissue cleanly around the CA to allow the ﬁlter paper
to contact the vessel wall directly and produce an even injury;
(3) underlying the CA with a ‘‘U’’ shaped piece of black plastic to
separate it from surrounding tissue, prevent FeCl3 diffusion, and
block background ﬂuorescence. This strategy is very important
when using this model to examine vessel wall reactive oxygen
species formation by injection of free radical indicator into the
blood system [26]; (4) directly injecting a ﬂuorescence dye into
the jugular vein to label platelets in vivo. This does not affect
platelet count or function, and obviates the need to sacriﬁce
additional animals as platelet donors.
Dose dependence of FeCl3-induced vessel occlusion time
We previously have reported that deletion of cd36 prolonged
vessel occlusion times [13]. We now used wt and cd36 null mice,which are unable to bind and respond to oxidized lipoprotein
particles and apoptotic cell particles, as tools to compare different
concentration of FeCl3 on thrombosis. No thrombi were observed
in the absence of FeCl3 application, showing that the surgical
procedures did not induce vascular injury (Fig. 2). Treatment of
CA with 2.5% FeCl3 for 1 min immediately induced formation of
scattered tiny thrombi in wtmice (Fig. 2A, column 1 min, arrows).
With time, the thrombi became larger, but at 30 min those were
not large enough to impact blood ﬂow. There were no thrombi
formed in 2 of the 3 cd36 null mice and only 4 tiny thrombi were
observed (starting at 8 min) in the third mouse.
Treatment with 5% FeCl3 for 1 min immediately induced
thrombi formation in wt and cd36 null mice, and the border of
the injured area was easy to identify (not shown). The thrombi
formed initially were smaller in cd36 null mice than in wt mice
(Fig. 2B). These initial thrombi were washed away by the blood
stream, so fewer thrombi were seen at 2 min. Thrombi started to
enlarge 3–4 min after removing the ﬁlter paper and these later
forming thrombi were stable and usually did not wash away.
The thrombi in wt mice formed faster and were larger than those
in cd36 null mice; cessation of blood ﬂow was seen in 3 of the
5 wt mice with an average vessel occlusion time of 23 min while
none of the cd36 null mice showed ﬂow cessation within the
30 min of observation.
Treatment of the vessels with 7.5% FeCl3 induced more rapid
increase in the size of thrombi in wt mice, but had no obvious
difference in cd36 null mice (Fig. 2C). As reported previously [27],
this concentration of FeCl3 induced vessel occlusion in both types
of mice; however, the vessel occlusion time was signiﬁcantly
elongated in cd36 null mice. When the FeCl3 concentration was
10% or greater the vessel wall oxidation injury was presumably
W. Li et al. / Redox Biology 1 (2013) 50–5554maximal (Fig. 2D) and no differences in occlusion time were seen
between the two types of mice. Fig. 3 shows vessel occlusion time
plotted as a function of FeCl3 and demonstrates a shift to the right
of the response curve in cd36 null mice compared to wt, suggest-
ing a pro-thrombotic effect of CD36. These data are also consis-
tent with our recent data that cd36 deletion induced an
antioxidant effect on the vessel wall [14].5
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Fig. 3. Vessel occlusion times after different concentrations of FeCl3 treatment.
Mice were treated as in Fig. 2 and occlusion time assessed by intravital micro-
scopy. *po0.01 wt vs. cd36 null at the same concentration of FeCl3. One-way
ANOVA Bonferroni/Dunn was used to determine the differences among groups.
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Fig. 4. Duration of FeCl3 treatment on thrombosis. (A) Representative video images of t
treatment. Numbers indicate time in minutes after removing the ﬁlter paper. (B) Stat
treatments. One-way ANOVA (Bonferroni/Dunn) was used to determine the differenceWhen thrombi become larger and cover the entire area of
injury, it becomes difﬁcult to observe ﬂow (e.g. Fig. 2B, 8 min time
point in wt, and online video). This may be the reason why some
researchers think that this method is less sensitive than measure-
ment of blood ﬂow by transonic ﬂowmeter. By surgically exposing
the CA over a sufﬁcient length and placing the ﬁlter paper close to
the distal site (Fig. 1I) we were able to observe and record the
normal area proximal to the site of injury as shown in Fig. 1I
(arrow) and Fig. 2C (e.g. 6–11 min in 7.5% FeCl3 treated wt
mouse), and blood ﬂow can be identiﬁed clearly. When blood
ﬂow ceases, numerous larger cells (leukocytes) start to adhere to
the vessel wall at the proximal site of the thrombi; therefore,
large cell accumulation can be used as a secondary marker for
oxidatve vascular damage. Flow usually stopped within 2 min of
the appearance of large cells (see online video for more informa-
tion). In our studies we recorded the time when blood ﬂow
completely stopped. This may differ from some studies using a
transonic ﬂow probe where background noise makes it difﬁcult to
determine the ﬂow precisely, especially when it falls to less than
10% of baseline [28].
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.redox.2012.11.001.
The duration of FeCl3 treatment correlates with time to vessel
occlusion
Published studies have used a range of exposure times of FeCl3
treatment, making comparisons among studies difﬁcult. To deter-
mine the effect of varying exposure times in this model system
we treated cd36 null mice with 5% FeCl3 for 1, 3 and 5 min.
As shown in Fig. 4, increasing the duration of FeCl3 exposure
dramatically increased the rate of thrombus enlargement andCl3 5% (min)
0.2
p = 0.02
p = 0.006
20
8’30” stopped
no stop
12 16 24 30
3 5
hrombi in CA exposed to 5% FeCl3 for 1, 3 or 5 min. ‘‘Before’’ indicates before FeCl3
istical analysis of vessel occlusion time. N¼3 for 1 min and n¼5 for 3 and 5 min
s among groups. Data are represented as mean7SEM.
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showed that cd36 deletion protects VSMC from oxidant stress
and reduces the amount of microparticles in the circulation after
FeCl3 injury. We also showed that microparticles contribute to
thrombosis by interacting with platelet CD36 [13]. Others have
shown that FeCl3-injury induces release of endothelial cell-
derived FeCl3-ﬁlled ‘‘buds’’ that are rich in tissue factor and may
contribute to thrombosis [21], while VSMC-derived tissue factor
can contribute to macrovascular thrombosis [29]. Our data
suggest that the duration of FeCl3 exposure is an important
component of the injury response in mouse models, perhaps by
inﬂuencing the level of endothelial and VSMC injury and micro-
particles release after exposing the vessel to oxidative stress.
In summary, we have reﬁned and standardized components of
the FeCl3-indcued vascular injury model to produce a highly
reproducible injury response where we can quantitate blood ﬂow
cessation accurately by intravital microscopy. This allowed us to
generate reproducible results with low variance [4,12–15,22,30]
to demonstrate FeCl3 dose and exposure duration, and hence
oxidative insult, inﬂuences thrombosis in vivo.Contribution of authors
Dr. Li performed the experiments, data analysis and wrote the
paper. Dr. McIntyre and Dr. Silverstein contributed to read and
write the paper critically.Conﬂict of interest statement
The authors have no conﬂicts of interest related to this study.Acknowledgment
This study was supported by NIH grants HL81011 and HL092747
(to R. L. Silverstein).
References
[1] J. Sanz, P.R. Moreno, V. Fuster, The year in atherothrombosis, Journal of the
American College of Cardiology 60 (10) (2012) 932–942.
[2] T.A. Meadows, D.L. Bhatt, Clinical aspects of platelet inhibitors and thrombus
formation, Circulation Research 100 (9) (2007) 1261–1275, May 11.
[3] D.O. Abegunde, C.D. Mathers, T. Adam, M. Ortegon, K. Strong, The burden and
costs of chronic diseases in low-income and middle-income countries, Lancet
370 (9603) (2007) 1929–1938.
[4] R.L. Silverstein, W. Li, Y.M. Park, S.O. Rahaman, Mechanisms of cell signaling
by the scavenger receptor CD36: implications in atherosclerosis and throm-
bosis, Transactions of the American Clinical and Climatological Association
121 (2010) 206–220.
[5] I.M. Fearon, S.P. Faux, Oxidative stress and cardiovascular disease: novel tools
give (free) radical insight, Journal of Molecular and Cellular Cardiology 47 (3)
(2009) 372–381.
[6] P. Libby, Inﬂammation in atherosclerosis, Nature 420 (6917) (2002) 868–874.
[7] G. Vilahur, T. Padro, L. Badimon, Atherosclerosis and thrombosis: insights
from large animal models, Journal of Biomedicine and Biotechnology 2011
(2011) 907575.[8] T. Thijs, H. Deckmyn, K. Broos, Model systems of genetically modiﬁed
platelets, Blood 119 (7) (2012) 1634–1642.
[9] R.J. Westrick, M.E. Winn, D.T. Eitzman, Murine models of vascular thrombosis
(Eitzman series), Arteriosclerosis, Thrombosis, and Vascular Biology 27 (10)
(2007) 2079–2093.
[10] S.M. Day, J.L. Reeve, D.D. Myers, W.P. Fay, Murine thrombosis models, Journal
of Thrombosis and Haemostasis 92 (3) (2004) 486–494.
[11] H.C. Whinna, Overview of murine thrombosis models, Thrombosis Research
122 (1) (2008) S64–S69.
[12] K. Chen, W. Li, J. Major, S.O. Rahaman, M. Febbraio, R.L. Silverstein, Vav
guanine nucleotide exchange factors link hyperlipidemia and a prothrombo-
tic state, Blood (2011) 22.
[13] A. Ghosh, W. Li, M. Febbraio, R.G. Espinola, K.R. McCrae, E. Cockrell, et al.,
Platelet CD36 mediates interactions with endothelial cell-derived micropar-
ticles and contributes to thrombosis in mice, Journal of Clinical Investigation
118 (5) (2008) 1934–1943.
[14] W. Li, M. Febbraio, S.P. Reddy, D.Y. Yu, M. Yamamoto, R.L. Silverstein, CD36
participates in a signaling pathway that regulates ROS formation in murine
VSMCs, Journal of Clinical Investigation 120 (11) (2010) 3996–4006.
[15] K. Chen, M. Febbraio, W. Li, R.L. Silverstein, A speciﬁc CD36-dependent
signaling pathway is required for platelet activation by oxidized low-density
lipoprotein, Circulation Research 102 (12) (2008) 1512–1519.
[16] K.D. Kurz, B.W. Main, G.E. Sandusky, Rat model of arterial thrombosis
induced by ferric chloride, Thrombosis Research 60 (4) (1990) 269–280.
[17] S. Konstantinides, K. Schafer, T. Thinnes, D.J. Loskutoff, Plasminogen activator
inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after
vascular injury in mice, Circulation 103 (4) (2001) 576–583.
[18] R.J. Leadley Jr., S.R. Morgan, R. Bentley, J.S. Bostwick, C.J. Kasiewski, C. Heran,
et al., Pharmacodynamic activity and antithrombotic efﬁcacy of RPR120844,
a novel inhibitor of coagulation factor Xa, Journal of Cardiovascular Pharma-
cology 34 (6) (1999) 791–799.
[19] E. Marsh Lyle, S.D. Lewis, E.D. Lehman, S.J. Gardell, S.L. Motzel, J.J. Lynch Jr.,
Assessment of thrombin inhibitor efﬁcacy in a novel rabbit model of
simultaneous arterial and venous thrombosis, Journal of Thrombosis and
Haemostasis 79 (3) (1998) 656–662.
[20] K.J. Woollard, S. Sturgeon, JP Chin-Dusting, H.H. Salem, S.P. Jackson, Erythrocyte
hemolysis and hemoglobin oxidation promote ferric chloride-induced vascular
injury, Journal of Biological Chemistry 284 (19) (2009) 13110–13118.
[21] A. Eckly, B. Hechler, M. Freund, M. Zerr, J.P. Cazenave, F. Lanza, et al.,
Mechanisms underlying FeCl3-induced arterial thrombosis, Journal of
Thrombosis and Haemostasis 9 (4) (2011) 779–789.
[22] J.O. Robertson, W. Li, R.L. Silverstein, E.J. Topol, J.D. Smith, Deﬁciency of LRP8
in mice is associated with altered platelet function and prolonged time for
in vivo thrombosis, Thrombosis Research 123 (4) (2009) 644–652.
[23] W. Zhu, W. Li, R.L. Silverstein, Advanced glycation end products induce a
prothrombotic phenotype in mice via interaction with platelet CD36, Blood
119 (25) (2012) 6136–6144.
[24] R. Le Menn, L. Bara, M. Samama, Ultrastructure of a model of thrombogenesis
induced by mechanical injury, Journal of Submicroscopic Cytology 13 (4)
(1981) 537–549.
[25] B.C. Cooley, Murine models of thrombosis, Thrombosis Research 129 (2) (2012)
S62–S64.
[26] W. Li, M. Febbraio, S.P. Reddy, D.Y. Yu, M. Yamamoto, R.L. Silverstein, CD36
participates in a signaling pathway that regulates ROS formation in murine
VSMCs, Journal of Clinical Investigation 120 (11) (2010) 3996–4006.
[27] A. Ghosh, W. Li, M. Febbraio, R.G. Espinola, K.R. McCrae, E. Cockrell, et al.,
Platelet CD36 mediates interactions with endothelial cell-derived micropar-
ticles and contributes to thrombosis in mice, The Journal of Clinical
Investigation 118 (5) (2008) 1934–1943.
[28] A.P. Owens 3rd, Y. Lu, H.C. Whinna, C. Gachet, W.P. Fay, N. Mackman,
Towards a standardization of the murine ferric chloride-induced carotid
arterial thrombosis model, Journal of Thrombosis and Haemostasis 9 (9)
(2011) 1862–1863.
[29] L. Wang, C. Miller, R.F. Swarthout, M. Rao, N. Mackman, M.B. Taubman,
Vascular smooth muscle-derived tissue factor is critical for arterial throm-
bosis after ferric chloride-induced injury, Blood 113 (3) (2009) 705–713.
[30] J. Liu, W. Li, R. Chen, T.M. McIntyre, Circulating biologically active oxidized
phospholipids show on-going and increased oxidative stress in older male
mice, Redox Biology(2013).
